Back to News
Market Impact: 0.28
Sandoz Partners With MAbxience On Hemophilia Biosimilar Program
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Sandoz announced a licensing, development, manufacturing and commercialization agreement with mAbxience to develop a proposed biosimilar version of emicizumab. The deal expands Sandoz's biosimilar pipeline into hemophilia for the first time, creating a potential new growth opportunity in a specialized treatment market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
SDZ0.58
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead